

117TH CONGRESS  
2D SESSION

# H. RES. 1506

Expressing support for continued investment to complete the development  
of an HIV vaccine.

---

## IN THE HOUSE OF REPRESENTATIVES

DECEMBER 1, 2022

Ms. WILLIAMS of Georgia (for herself and Ms. LEE of California) submitted  
the following resolution; which was referred to the Committee on Energy  
and Commerce

---

## RESOLUTION

Expressing support for continued investment to complete the  
development of an HIV vaccine.

Whereas HIV affects the entire globe and exists in a variety  
of subtypes;

Whereas, in 2019, the estimated number of new HIV infec-  
tions in adults and adolescents was approximately  
34,800, and the overall rate of new HIV infections was  
12.6 cases per 100,000 people in the United States;

Whereas, at the end of 2019, the estimated HIV prevalence  
rate for persons 13 years of age and older in the United  
States was 431.0 per 100,000 people;

Whereas, as of 2019, Black Americans have a rate of HIV  
infection that is 8.1 times higher than that of White  
Americans;

Whereas, in 2019, there were 6.0 cases of HIV per 100,000 people that progressed from HIV to AIDS in the United States;

Whereas, at the end of 2019, the AIDS prevalence rate among adults and adolescents in the United States was estimated at 192.3 per 100,000 people;

Whereas, each year, more than 12,000 people with AIDS die in the United States;

Whereas the people diagnosed with HIV in 2018 in the United States will pay a combined estimated lifetime total of \$13,700,000,000 in direct medical expenses;

Whereas it is estimated that patients on antiretroviral therapy with access to discounted medication have lifetime medical costs averaging \$420,285, which rises to an average of \$1,079,999 for patients without such access, based on an estimated life expectancy of 37.31 years after diagnosis;

Whereas, in fiscal year 2022 alone, United States Federal domestic discretionary funding for HIV/AIDS programs totaled \$7,425,800,000;

Whereas the United States has contributed a total of \$23,170,000,000 since 2002 to the Global Fund to Fight AIDS, Tuberculosis and Malaria, a multilateral effort supported by a number of countries and nongovernmental organizations;

Whereas alternatives for preventing HIV transmission, formerly limited to abstinence, education, circumcision, and condoms, now include HIV prevention medicines such as preexposure prophylaxis (PrEP) and postexposure prophylaxis (PEP);

Whereas 3 HIV vaccines (BG505 MD39.3 mRNA, BG505 MD39.3 gp151 mRNA, and BG505 MD39.3 gp151 CD4KO mRNA) are currently in National Institutes of Health-funded phase 1 trials;

Whereas President Biden has pledged to develop and implement a comprehensive national HIV/AIDS strategy that will include a focus on reducing HIV incidence; and

Whereas continued government investment toward a viable HIV vaccine has the potential to improve public health in the United States: Now, therefore, be it

1       *Resolved*, That the House of Representatives strongly  
 2 encourages domestic efforts in the public and private sec-  
 3 tors to invest in and complete the development of a vaccine  
 4 for HIV.

○